Pediatric Oncology Labeling Should Reflect Exploratory Approach – Pazdur
Executive Summary
Oncologic drug pediatric labeling should reflect the exploratory nature of the field, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, said during an advisory committee meeting March 4